Cargando…

Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Detalles Bibliográficos
Autores principales:	Zhang, Chi, Stockwell, Simon R., Elbanna, May, Ketteler, Robin, Freeman, Jamie, Al-Lazikani, Bissan, Eccles, Suzanne, De Haven Brandon, Alexis, Raynaud, Florence, Hayes, Angela, Clarke, Paul A., Workman, Paul, Mittnacht, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160058/ https://www.ncbi.nlm.nih.gov/pubmed/32094403 http://dx.doi.org/10.1038/s41388-020-1221-8

Ejemplares similares

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
por: Zhang, Chi, et al.
Publicado: (2019)

Blocking the survival of the nastiest by HSP90 inhibition
por: Workman, Paul, et al.
Publicado: (2016)

Distinctive Behaviors of Druggable Proteins in Cellular Networks
por: Mitsopoulos, Costas, et al.
Publicado: (2015)

SiGNet: A signaling network data simulator to enable signaling network inference
por: Coker, Elizabeth A., et al.
Publicado: (2017)

Polypharmacology in Precision Oncology: Current Applications and Future  Prospects
por: Antolin, Albert A., et al.
Publicado: (2016)

Evolution of kinase polypharmacology across HSP90 drug discovery
por: Antolin, Albert A., et al.
Publicado: (2021)

Workflow for High-content, Individual Cell Quantification of Fluorescent Markers from Universal Microscope Data, Supported by Open Source Software
por: Stockwell, Simon R., et al.
Publicado: (2014)

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
por: Dale, Trevor, et al.
Publicado: (2015)

The kinase polypharmacology landscape of clinical PARP inhibitors
por: Antolin, Albert A., et al.
Publicado: (2020)

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
por: Mallinger, Aurélie, et al.
Publicado: (2016)

Objective, Quantitative, Data-Driven Assessment of Chemical Probes
por: Antolin, Albert A., et al.
Publicado: (2018)

Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
por: Asghar, Uzma S., et al.
Publicado: (2022)

Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
por: Saturno, Grazia, et al.
Publicado: (2013)

Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division
por: Clemm von Hohenberg, Katharina, et al.
Publicado: (2022)

2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
por: Mallinger, Aurélie, et al.
Publicado: (2016)

Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches
por: Darby, John F., et al.
Publicado: (2020)

Mechanism-Based Screen Establishes Signalling Framework for DNA Damage-Associated G1 Checkpoint Response
por: Richardson, Elizabeth, et al.
Publicado: (2012)

RB in DNA repair
por: Huang, Paul H., et al.
Publicado: (2015)

The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use
por: Antolin, Albert A, et al.
Publicado: (2022)

CDK control pathways integrate cell size and ploidy information to control cell division
por: Patterson, James Oliver, et al.
Publicado: (2021)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity
por: Matsuda, Shinya, et al.
Publicado: (2017)

canSAR: update to the cancer translational research and drug discovery knowledgebase
por: Coker, Elizabeth A, et al.
Publicado: (2019)

Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer
por: Chung, I-Hsiao, et al.
Publicado: (2015)

Rational design of non-resistant targeted cancer therapies
por: Martínez-Jiménez, Francisco, et al.
Publicado: (2017)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

Class 3 Semaphorin Mediates Dendrite Growth in Adult Newborn Neurons through Cdk5/FAK Pathway
por: Ng, Teclise, et al.
Publicado: (2013)

canSAR: an integrated cancer public translational research and drug discovery resource
por: Halling-Brown, Mark D., et al.
Publicado: (2012)

canSAR: updated cancer research and drug discovery knowledgebase
por: Bulusu, Krishna C., et al.
Publicado: (2014)

canSAR chemistry registration and standardization pipeline
por: Dolciami, Daniela, et al.
Publicado: (2022)

Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia
por: Bavetsias, Vassilios, et al.
Publicado: (2012)

Cytoplasmic division cycles without the nucleus and mitotic CDK/cyclin complexes
por: Bakshi, Anand, et al.
Publicado: (2023)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9
por: Rye, Carl S., et al.
Publicado: (2016)

canSAR: update to the cancer translational research and drug discovery knowledgebase
por: di Micco, Patrizio, et al.
Publicado: (2022)

Tuning Local Hydration Enables a Deeper Understanding of Protein–Ligand Binding: The PP1-Src Kinase Case
por: Spitaleri, Andrea, et al.
Publicado: (2020)

Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling
por: Stockwell, Simon R., et al.
Publicado: (2012)

Backtracking on FAK
por: Leslie, Mitch
Publicado: (2008)

FAK monitoring
por: Metzmacher, K D
Publicado: (1974)

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors
por: Lainchbury, Michael, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mm44n7amrtgd5fv9vn04o5r0o4